Humedics has developed the LiMAx breath-test diagnostic system, which comprises a CE-marked medical device, breath masks and a diagnostic drug to quantitatively determine individual liver function within minutes. The test enables clinicians to tailor treatment strategies based on a patient’s liver capacity. Current applications include assessment before and after liver transplantation, liver surgery planning to evaluate resection risk, and evaluation of diseases such as liver cirrhosis. The company is led by Managing Director Erwin de Buijzer and is based in Berlin, Germany. Humedics closed a €6.3m Series C financing round to support its next stage of growth. The proceeds are intended to fund the European market entry of the LiMAx test and the corresponding FLIP diagnostic device. Humedics develops a proprietary, CE-marked diagnostic system (the LiMAx test) that quantitatively determines individual liver function capacity within minutes. The system comprises the FLIP medical device and an intravenous diagnostic drug preparation (13C-Methacetin). Current applications include assessment before and after liver transplantation, planning of liver surgeries, and evaluation of liver diseases such as cirrhosis. The company completed its first venture financing round to support final development and early commercialization. The amount raised was undisclosed; management intends to deploy the funds to finish development and begin commercial rollout. Humedics is led by Dr. Klaus Stöckemann (Chairman) and Managing Director Wilfried Heyne and is based in Berlin, Germany. Humedics commercializes an innovative method for instantaneous measurement of liver function at the patient’s bedside. The newly formed spin-off from Freie Universität Berlin and the Charité university hospital is based in Grossbeeren, Germany. The company plans to develop production devices and pursue regulatory approval for its bedside liver-function measurement technology. Humedics received a €500,000 investment from High‑Tech Gründerfonds to begin development and the approval process. The funds are earmarked to start production-device development and the regulatory filings required for clinical use. No revenue, user, or other operating metrics were disclosed in the article.

Total raised

$9M

Funding rounds

3

Latest round

Series C

Latest activity

Nov 2014